WO2000074684A1 - Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use - Google Patents
Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use Download PDFInfo
- Publication number
- WO2000074684A1 WO2000074684A1 PCT/US2000/040061 US0040061W WO0074684A1 WO 2000074684 A1 WO2000074684 A1 WO 2000074684A1 US 0040061 W US0040061 W US 0040061W WO 0074684 A1 WO0074684 A1 WO 0074684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical formulation
- woman
- derivatives
- progestin
- postmenopausal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention relates to pharmaceutical formulations and methods for treating postmenopausal and perimenopausal women.
- Postmenopausal women including young women who suffer from ovarian dysfunction due to surgical, radiation, or chemotherapy induced ablation, for example, typically exhibit particular physiological signs associated with impairment of ovarian function. For example, such women typically experience a loss of calcium from the skeleton, leading to a reduction in bone density or in the quantity of bone. In addition, such women may have increased cholesterol levels, leading to atherosclerosis. Other symptoms include depression, headaches , and nausea . Perimenopausal women experience a change in the intermenstrual cycle interval, along with other associated symptoms of estrogen deficiency, such as vasomotor flushes, vaginal dryness, or worsening premenstrual syndromes .
- An exemplary pharmaceutical formulation of the invention includes (i) an androgen or a selective androgen receptor modulator (SARM) , (ii) an estrogen or a selective estrogen receptor modulator (SERM) , and (iii) a progestin or a selective progestin receptor modulator (SPRM) in a pharmaceutically acceptable carrier.
- SARM selective androgen receptor modulator
- SERM selective estrogen receptor modulator
- SPRM progestin or a selective progestin receptor modulator
- the invention features a pharmaceutical formulation that includes (i) a SERM and (ii) an androgen or a SARM in a pharmaceutically acceptable carrier.
- this pharmaceutical formulation also includes (iii) a progestin or a SPRM.
- Pharmaceutical formulations containing a therapeutically effective amount of a SERM and an androgen or SARM, and optionally a progestin or SPRM, can be used to treat postmenopausal women and perimenopausal women.
- a pharmaceutical formulation that includes (i) a SERM and (ii) an estrogen, and optionally (iii) a progestin or SPRM.
- a pharmaceutical formulation containing a therapeutically effective amount of the SERM and estrogen, and optionally progestin, can be used in methods of treating postmenopausal and perimenopausal women.
- the invention includes a pharmaceutical formulation containing (i) a SERM, (ii) an estrogen, and (ii) an androgen or SARM, and optionally (iv) a progestin or SPRM.
- a pharmaceutical formulation containing the SERM, estrogen, androgen, and optionally progestin, in a therapeutically effective amount can be used in methods of treating postmenopausal and perimenopausal women.
- estrogens progestins, androgens, SERMs, SARMs, and SPRMs
- suitable estrogens include conjugated estrogens, esterified estrogens, estradiol valerate, estradiol benzoate, 17- ⁇ estradiol, estradiol cypionate, estrone, piperazine estrone sulfate, estriol, ethyl estradiol, polyestradiol phosphate, estrone potassium sulfate, benzestrol, chlorotrianisene, methallenestril, dienestrol, diethylstilbestrol diphosphate, mestranol, diethylstilbestrol (DES) , quinestranol, and phytoestrogens .
- Animal-derived estrogens e.g., equine estrogens
- metabolic derivatives also are suitable for use in the invention, and are commercially available.
- progestins examples include progesterone, 17-hydroxy progesterone derivatives, 19-nor testosterone derivatives, norethindrone, norethindrone acetate, norethynodrel, norgestrel, norgestimate, ethynodiol diacetate, allylestrenol, lynoestrenol, fuingestanol acetate, medrogestone, norgestrienone, dimethiderome, ethisterone, cyproterone levo-norgestrel, dl-norgestrel, cyproterone acetate, gestodene, desogestrol , phytoprogestins, dydrogesterone, ethynodiol diacetate, medroxyprogesterone acetate, phytoprogestins, and megestrol acetate.
- Animal- derived progestins e.g
- Suitable androgens include testosterone, methyltestosterone, fluoxymesterone, testosterone cypionate, testosterone enanthate, testosterone propionate, oxymetholone , ethylestrenol, oxandrolone, nandrolone phenpropionate, nandrolone decanoate, stanozolol, dromostanolone propionate, androstenedione, dehydropepiandrosterone, dehydroepiandrosterone sulfate (DHEAS) , dihydrotestosterone, and phytoandrogens .
- Animal-derived androgens e.g., equine androgens
- metabolic derivatives also are suitable for use in the invention.
- SERMs examples include tamoxifen, raloxifene, clomiphene, droloxifene, idoxifene, toremifene, tibolone, ICI 182,780, ICI 164,384, diethylstilbesterol, genistein, nafoxidine, moxestrol, 19-nor-progesterone derivatives, and 19- nor-testosterone derivatives.
- SARMs include cyproterone acetate, hydroxyflutamide, bicalutamide, spironolactone, 4- (trifluoromethyl) -2 (1H) - pyrrolidino [3 , 2-g] quinolinone derivatives, 1,2- dihydropyridono [5, 6-g] quinoline derivatives, and piperidino [3 , 2-g] quinolinone derivatives .
- SPRMs examples include RU486, CDB2914, 19-nor-progesterone derivatives, 19-nor- testosterone derivatives, 6-aryl-l, 2-dihydro-2 , 2 , 4- trimethylquinoline derivatives, 5-aryl-l, 2-dihydro- 5H-chromeno [3 , 4-f] quinoline derivatives, 5-alkyl 1, 2-dihydrochomeno [3 , 4-f] quinoline derivatives, and 6-thiophenehydroquinoline derivatives .
- the pharmaceutical formulations described herein are contained within a transdermal patch or an intravaginal ring for delivery of the pharmaceutical formulation to the woman.
- transdermal routes e.g., through the use of topically applied creams, ointments, and the like
- intravaginal routes e.g., through the use of suppositories, creams, and the like
- the pharmaceutical formulations can be prepared for administration via routes such as oral, intranasal, buccal , ocular, aural, injectable depot, subcutaneous, intraperitoneal, intrauterine, sublingual, or intramuscular routes of administration.
- routes of administration can be used to deliver the estrogen, androgen, progestin, SERM, SARM, and/or SPRM to the woman (e.g., oral and transdermal routes) .
- multiple estrogens, androgens, progestins, SERMs, SARMs, and/or SPRMs can be used to prepare the pharmaceutical formulation or to treat the woman in lieu of a single estrogen, androgen, progestin, SERM, SARM, and/or SPRM.
- a "postmenopausal" woman is one who in the absence of hormone replacement therapy or other medication would experience at least 12 months of amenorrhea or levels of serum follicle-stimulating hormone greater than 30 mlU/ml .
- a "perimenopausal" woman is one who in the absence of hormone replacement therapy or other medication would experience a change in her intermenstrual cycle interval and have associated symptoms of estrogen deficiency, such as vasomotor flushes, vaginal dryness, and worsening premenstrual syndrome. Also included are women who in the absence of hormone replacement therapy or other medication would experience less than 12 months of amenorrhea .
- an "androgen” is a natural or synthetic agent that stimulates activity of the accessory male sex organs and/or muscle development and/or encourages development of male sex characteristics.
- suitable androgens include, without limitation, testosterone, methyltestosterone, fluoxymesterone, testosterone cypionate, testosterone enanthate, testosterone propionate, oxymetholone, ethylestrenol, oxandrolone, nandrolone phenpropionate, nandrolone decanoate, testosterone buccilate, stanozolol, dromostanolone propionate, androstenedione, dehydropepiandrosterone, DHEAS, dihydrotestosterone, phytoandrogens , animal-derived androgens, and metabolic derivatives of animal- derived androgens .
- progestin is an agent, natural or synthetic, that effects some or all of the biological changes produced by progesterone, which is a hormone of the corpus luteum.
- progesterone which is a hormone of the corpus luteum.
- a progestin can induce secretory changes in the endometrium.
- progestins include, without limitation, progesterone, 17-hydroxy progesterone derivatives, 19-nor-testosterone derivatives, 19-nor-progesterone derivatives norethindrone, norethindrone acetate, norethynodrel, norgestrel, norgestimate, ethynodiol diacetate, allylestrenol, lynoestrenol , fuingestanol acetate, medrogestone, norgestrienone, dimethiderome, ethisterone, cyproterone levo-norgestrel, dl- norgestrel, cyproterone acetate, gestodene, desogestrol, dydrogesterone, ethynodiol diacetate, medroxyprogesterone acetate, megestrol acetate, phytoprogestins, animal-derived prog
- estradiol is an agent, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones such as estradiol.
- estradiol also encompasses "conjugated estrogens, " which are an amorphous preparation of naturally occurring, water- soluble, conjugated forms of mixed estrogens that typically are obtained from the urine of pregnant mares (e.g., sodium estrone sulfate). Also included are “esterified estrogens, " which are a mixture of the sodium salts of sulfate esters or glucanoride of sulfate conjugates of estrogenic substances.
- suitable estrogens include, without limitation, estradiol valerate, estradiol benzoate, 17- ⁇ estradiol, estradiol cypionate, estrone, piperazine estrone sulfate, estriol, ethyl estradiol, polyestradiol phosphate, estrone potassium sulfate, benzestrol, chlorotrianisene, methallenestril, dienestrol, diethylstilbestrol diphosphate, mestranol, DES, quinestranol , phytoestrogens, animal-derived estrogens (e.g., equine estrogens) , and metabolic derivatives of animal-derived estrogens.
- SERM is a compound that is an estrogen analog and which exerts tissue-selective effects. Such compounds can function as estrogen antagonists or partial agonists.
- a "selective androgen receptor modulator” (SARM) is a compound that is an androgen analog and which exerts tissue-selective effects. Such compounds can function as androgen antagonists or partial agonists.
- a “selective progestin receptor modulator” (SPRM) is a compound that is an progesterone analog and which exerts tissue-selective effects. Such compounds can function as progesterone antagonists or partial agonists.
- SPRM selective progestin receptor modulator
- the hormone replacement methods of the invention can be used to restore normal physiologic levels of all gonadal steroids for optimal management of symptoms .
- Other features and advantages of the invention will be evident from the following detailed description of the preferred embodiments, and from the claims. Description of the Preferred Embodiments The pharmaceutical formulations and therapeutic methods of the invention are suitable for virtually all postmenopausal and perimenopausal women .
- compositions of the invention include a pharmaceutically acceptable carrier and one of the following combinations of active ingredients:
- A (i) an androgen or SARM, (ii) an estrogen or SERM, and (iii) a progestin or SPRM;
- B (i) a SERM and (ii) an androgen or SARM, and optionally (iii) a progestin or SPRM;
- (D) (i) a SERM, (ii) an estrogen, and (iii) an androgen or SAM, and optionally (iv) a progestin or SPRM.
- Such formulations typically contain from about 0.1 to 90% by weight (such as 1 to 20% or 1 to 10%) of the active ingredients in a pharmaceutically acceptable carrier.
- the pharmaceutical formulations are prepared for delivery via an intravaginal ring.
- Intravaginal rings are well known in the art, and such rings can readily be adapted to contain the above-described combinations of active ingredients in a pharmaceutically acceptable carrier.
- an oil or water is used as the carrier.
- intravaginal rings examples include Suitable intravaginal rings in U.S. Patents No. 4,762,717; 5,130,137; 4,012,496; 3,854,480; 4,391,797; 4,591,496; and 5,330,768, which are incorporated herein by reference .
- Typical intravaginal rings that can be adapted for use in the invention are made of ethylvinylacetate .
- the intravaginal ring includes estrogen or a SERM at a level sufficient to recreate estrogen effects equivalent to those encountered in the early follicular phase of a typical, normal menstrual cycle.
- the androgen or SARM typically is contained within the ring at a level sufficient to recreate androgen effects equivalent to those encountered in the early follicular phase of a typical, normal menstrual cycle.
- the progestin or SPRM is included at a level sufficient to recreate progestin effects equivalent to those encountered in the luteal phase of a typical, normal menstrual cycle. Examples of suitable dosages are described below.
- the pharmaceutical formulations of the invention are contained within a transdermal patch.
- transdermal patches are known in the art and can readily be adapted to contain and deliver the pharmaceutical formulations of the invention. Examples of suitable transdermal patches are disclosed in U.S. Patents No. 5,223,261; 3,598,123; 4,460,372; 3,598,122; 4,573,996; and 4 , 624 , 665 , which are incorporated herein by reference.
- Typical transdermal patches have a flexible backing, a drug reservoir layer, a semipermeable membrane, and an adhesive layer coated on the exterior surface of the semipermeable membrane.
- Theratech patch technology for example, can be used in the invention.
- the patch may contain a skin penetration enhancer (e.g., a fatty acid ester of a fatty acid such as ethyl oleate, glyceryl monolaurate, and/or isopropyl myristate) .
- a skin penetration enhancer e.g., a fatty acid ester of a fatty acid such as ethyl oleate, glyceryl monolaurate, and/or isopropyl myristate
- the pharmaceutical formulation is contained within the adhesive coating, rather than in a distinct drug reservoir layer.
- a patch may contain, for example, a flexible backing (e.g., polyethylene, polypropylene, polyurethane, and the like) and a pressure-sensitive adhesive coating contiguously adhered to one surface of the backing and containing a homogenous mixture of: (i) an acrylic polymer containing a hydrophobic monomeric acrylic or methacrylic ester of an alkyl alcohol (containing 4-10 carbons) , polyanhydrides, polyvinylacetate, polylactide or polyglycolide mixes; ( ii) the active ingredients, each in an amount of about 0.2 to 12 percent of the total weight of the adhesive coating; and (iii) a skin penetration enhancer that includes isopropyl myristate and glyceryl monolaurate each in an amount of about 1 to 20 percent of the weight of the adhesive coating.
- Solid formulations for oral administration can contain suitable carriers or excipients, such as corn starch, gelatin, lactose, liposomes, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodium chloride, or alginic acid.
- suitable carriers or excipients such as corn starch, gelatin, lactose, liposomes, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodium chloride, or alginic acid.
- Disintegrators that can be used include, without limitation, micro- crystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
- Tablet binders that may be used include acacia, methylcellulose, sodium carboxy ethylcellulose, polyvinylpyrrolidone (Povidone) , hydroxypropyl methylcellulose, sucrose, starch, and ethylcellulose .
- Lubricants that may be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.
- Liquid formulations for oral or sublingual administration typically are prepared in water or other aqueous vehicles.
- the liquid formulations also can include solutions, emulsions, syrups, and elixirs containing, together with the active ingredients, wetting agents, sweeteners, and coloring and flavoring agents.
- Various liquid and powder formulations can be prepared by conventional methods for inhalation by the woman.
- Injectable formulations can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polylactide, polyglycolide, polyols, (glycerol, propylene glycol, liquid polyethylene glycol, and the like) .
- the compounds may be administered by the drip method, whereby a pharmaceutical formulation containing the active ingredients and a pharmaceutically acceptable carrier is infused.
- Pharmaceutically acceptable carries can include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable carriers.
- a sterile formulation containing the active ingredients can be administered in a pharmaceutical carrier such as Water-for-Injection, 0.9% saline, or 5% glucose solution.
- a topical semi-solid ointment formulation typically contains a concentration of the active ingredients from about 1 to 20% (e.g., 5 to 10%) in a carrier such as a pharmaceutical cream base.
- compositions for topical use include drops, tinctures, lotions, creams, solutions, and ointments containing the active ingredient and various supports and vehicles.
- the pharmaceutical formulations of the invention can be administered to the woman via a variety of combinations of routes of administration.
- an androgen, estrogen, and progestin can be combined and delivered transdermally (e.g., via a transdermal patch) .
- an estrogen can be administered orally, while the progestin and androgen are administered transdermally.
- an androgen, estrogen, and progestin are administered orally.
- the androgen, estrogen, and progestin can be administered via an intravaginal ring.
- Therapeutic Regimens Virtually all postmenopausal and perimenopausal women can be treated with the methods of the invention. If desired, such a woman can be identified as being in need of hormone replacement therapy (using standard criteria, as described, for example, by the American College of Physicians
- the androgen typically is administered at a daily dosage of 0.01 ⁇ g to 5 mg/kg of body weight (e.g., 1 ⁇ g/kg to 5 mg/kg)
- the estrogen typically is administered at a dosage of 0.01 ⁇ g/kg to 4 mg/kg (e.g., 0.2 ⁇ g/kg to 100 ⁇ g/kg)
- the progestin typically is administered at a dosage of 0.02 mg/kg to 200 mg/kg (e.g., 2 ⁇ g/kg to 10 mg/kg).
- a SARM typically is administered at a daily dosage of 0.01 ⁇ g/kg to 100 mg/kg of body weight (e.g., 1 ⁇ g/kg to 4 mg/kg)
- a SERM typically is administered at a dosage of 0.01 ⁇ g/kg to 100 ⁇ g/kg (e.g., 1 ⁇ g/kg to 2 mg/kg)
- a SPRM typically is administered at a dosage of O.Ol ⁇ g/kg to 100 mg/kg (e.g., 1 ⁇ g/kg to 30 mg/kg) .
- the pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose. Typically, the woman will be treated over the course of several months or years, or even life-long to ameliorate the signs and symptoms resulting from natural or induced impairment of ovarian function.
- the therapeutic regimen entails administering to the woman a pharmaceutical formulation containing each of (i) an androgen or SARM, (ii) an estrogen or SERM, and (iii) a progestin or SPRM at least once daily for 13 to 14 days, followed by administering each of (i) an estrogen or SERM and (ii) an androgen or SARM at least once daily for 13 to 14 days.
- a pharmaceutical formulation containing each of (i) an androgen or SARM, (ii) an estrogen or SERM, and (iii) a progestin or SPRM at least once daily for 13 to 14 days.
- the dosages listed above are suitable.
- the woman is treated with a pharmaceutical formulation containing each of (i) a SERM, (ii) an androgen or SARM, and, optionally, (iii) a progestin or SPRM.
- this pharmaceutical formulation is administered to the woman at least once daily (e.g., orally, or delivered by transdermal or depot methods) for at least 30 days, at the dosages listed above.
- the woman will be treated over the course of several months or years, or even life-long to relieve her of the signs and symptoms resulting from natural or induced impairment of ovarian function.
- the woman can be treated with a pharmaceutical formulation containing each of (i) a SERM and (ii) an estrogen, and, optionally, (iii) a progestin or SPRM.
- this pharmaceutical e.g., orally or delivered by transdermal or depot methods
- this pharmaceutical is administered to the woman at least once daily for at least 30 days at the dosages listed above.
- the woman will be treated over the course of several months or years, or even life-long to relieve her of the signs and symptoms resulting from natural or induced impairment of ovarian function.
- the woman can be treated with a pharmaceutical formulation containing each of (i) a SERM, (ii) an estrogen, (iii) an androgen or SARM, and, optionally, (iv) a progestin or SPRM.
- this pharmaceutical formulation is administered to the woman at least once daily for at least 30 days at the dosages listed above.
- the woman will be treated over the course of several months or years, or even life-long to relieve her of the signs and symptoms resulting from natural or induced impairment of ovarian function.
- the progestin can be given continuously or cyclicly (i.e., by administering it on only some of the days that the other drugs are administered) .
- Conventional methods known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation (s) to the woman.
- the pharmaceutical formulation will be administered to the woman by applying to the skin of the woman a transdermal patch containing the pharmaceutical formulation, and leaving the patch in contact with her skin (generally for 1 to 5 hours per patch) .
- an intravaginal ring containing the pharmaceutical formulation is inserted into the woman and left in place for 1 to 90 days (e.g., 15 to 30 days) per intravaginal ring.
- transdermal and intravaginal routes of administration can be used by applying conventional techniques.
- the pharmaceutical formulations can also be administered via other conventional routes (e.g., oral, subcutaneous, intraperitoneal, intrauterine, sublingual, or intramuscular routes) by using standard methods.
- the pharmaceutical formulations can be administered to the woman via injectable depot routes of administration such as by using 1, 3, or 6-month depot injectable or biodegradable materials and methods.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU51812/00A AU5181200A (en) | 1999-06-04 | 2000-06-02 | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
EP00936507A EP1187618A1 (en) | 1999-06-04 | 2000-06-02 | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
JP2001501220A JP2003501390A (en) | 1999-06-04 | 2000-06-02 | Pharmaceutical formulations for treating postmenopausal and menopausal women, and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13744099P | 1999-06-04 | 1999-06-04 | |
US60/137,440 | 1999-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000074684A1 true WO2000074684A1 (en) | 2000-12-14 |
Family
ID=22477447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/040061 WO2000074684A1 (en) | 1999-06-04 | 2000-06-02 | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1187618A1 (en) |
JP (1) | JP2003501390A (en) |
AU (1) | AU5181200A (en) |
WO (1) | WO2000074684A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092102A2 (en) * | 2001-05-16 | 2002-11-21 | Endeavor Pharmaceuticals | Treatment of conditions relating to hormone deficiencies by administration of progestins |
WO2003063859A1 (en) * | 2002-01-14 | 2003-08-07 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
WO2003082299A1 (en) * | 2002-04-03 | 2003-10-09 | Jencap Research Ltd. | Improved hormone replacement therapy |
WO2004022065A1 (en) * | 2002-09-05 | 2004-03-18 | Pantarhei Bioscience B.V. | Pharmaceutical application of 15- or 16- substituted testosterone analogues |
JP2004515531A (en) * | 2000-12-15 | 2004-05-27 | ノボ ノルディスク アクティーゼルスカブ | Use of estrogens in the manufacture of compositions containing estrogens for the treatment of atrophic vaginitis |
EP1494679A1 (en) * | 2002-04-03 | 2005-01-12 | Barr Laboratories, Inc. | Step-down estrogen therapy |
EP1522306A1 (en) * | 2003-10-08 | 2005-04-13 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof |
JP2005511725A (en) * | 2001-12-13 | 2005-04-28 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | Transdermal transport of compounds |
EP1583536A2 (en) * | 2003-01-17 | 2005-10-12 | Erik P. Castle | Method of treatment of prostate cancer and composition for treatment thereof |
US7030157B2 (en) | 2001-07-31 | 2006-04-18 | Pfizer Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
AU2002243411B2 (en) * | 2000-12-22 | 2007-02-08 | Barr Laboratories, Inc. | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
EP1862165A2 (en) * | 2001-11-29 | 2007-12-05 | GTX, Inc. | Prevention and treatment of androgen-deprivation induced hot flashes |
WO2007144151A1 (en) * | 2006-06-13 | 2007-12-21 | Bayer Schering Pharma Aktiengesellschaft | Step-down estrogen regimen for women receiving estrogen therapy |
US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
US8841342B2 (en) | 2002-08-09 | 2014-09-23 | Vital Health Sciences Pty. Ltd. | Carrier |
US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
WO2016028903A1 (en) * | 2014-08-20 | 2016-02-25 | Professional Compounding Centers Of America | Oral transmucosal pharmaceutical compositions including testosterone and a c-sperm |
US9314527B2 (en) | 2010-03-30 | 2016-04-19 | Phosphagenics Limited | Transdermal delivery patch |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
WO2020010205A1 (en) * | 2018-07-05 | 2020-01-09 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
EP3613418A1 (en) * | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
WO2020247653A1 (en) * | 2019-06-06 | 2020-12-10 | Evestra, Inc. | Hormonal contraception using a vaginal ring which releases estriol and trimegestone |
US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005298450A (en) * | 2004-04-15 | 2005-10-27 | Taisho Pharmaceut Co Ltd | Prophylactic or therapeutic agent composition for menopausal syndrome |
UY33103A (en) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | PARENTERAL PHARMACEUTICAL FORMULATION IN SUSPENSION, SUSTAINED RELEASE, IN LOW AND ULTRA LOW DOSE, IN HORMONAL THERAPY IN THE CLIMATE SYNDROME |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
US5846960A (en) * | 1991-06-28 | 1998-12-08 | Endorecherche, Inc. | Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds |
US5955455A (en) * | 1993-01-19 | 1999-09-21 | Endorecherche, Inc. | Therapeutic methods and delivery systems utilizing sex steroid precursors |
-
2000
- 2000-06-02 EP EP00936507A patent/EP1187618A1/en not_active Withdrawn
- 2000-06-02 AU AU51812/00A patent/AU5181200A/en not_active Abandoned
- 2000-06-02 JP JP2001501220A patent/JP2003501390A/en not_active Withdrawn
- 2000-06-02 WO PCT/US2000/040061 patent/WO2000074684A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5846960A (en) * | 1991-06-28 | 1998-12-08 | Endorecherche, Inc. | Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds |
US5955455A (en) * | 1993-01-19 | 1999-09-21 | Endorecherche, Inc. | Therapeutic methods and delivery systems utilizing sex steroid precursors |
US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132089B2 (en) | 2000-08-30 | 2015-09-15 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
JP4851057B2 (en) * | 2000-12-15 | 2012-01-11 | ノボ・ノルディスク・フェムケア・アーゲー | Use of estrogen in the manufacture of a composition containing estrogen for the treatment of atrophic vaginitis |
JP2004515531A (en) * | 2000-12-15 | 2004-05-27 | ノボ ノルディスク アクティーゼルスカブ | Use of estrogens in the manufacture of compositions containing estrogens for the treatment of atrophic vaginitis |
AU2002243411B2 (en) * | 2000-12-22 | 2007-02-08 | Barr Laboratories, Inc. | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
WO2002092102A2 (en) * | 2001-05-16 | 2002-11-21 | Endeavor Pharmaceuticals | Treatment of conditions relating to hormone deficiencies by administration of progestins |
WO2002092102A3 (en) * | 2001-05-16 | 2003-03-20 | Endeavor Pharmaceuticals | Treatment of conditions relating to hormone deficiencies by administration of progestins |
US8076319B2 (en) | 2001-05-16 | 2011-12-13 | Barr Laboratories, Inc. | Treatment of conditions relating to hormone deficiencies by administration of progestins |
US7683047B2 (en) | 2001-05-16 | 2010-03-23 | Barr Laboratories, Inc. | Treatment of conditions relating to hormone deficiencies by administration of progestins |
US7427609B2 (en) | 2001-05-16 | 2008-09-23 | Barr Laboratories, Inc. | Treatment of conditions relating to hormone deficiencies by administration of progestins |
US7030157B2 (en) | 2001-07-31 | 2006-04-18 | Pfizer Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
EP1862165A2 (en) * | 2001-11-29 | 2007-12-05 | GTX, Inc. | Prevention and treatment of androgen-deprivation induced hot flashes |
EP1862165A3 (en) * | 2001-11-29 | 2008-06-25 | GTX, Inc. | Prevention and treatment of androgen-deprivation induced hot flashes |
JP2005511725A (en) * | 2001-12-13 | 2005-04-28 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | Transdermal transport of compounds |
WO2003063859A1 (en) * | 2002-01-14 | 2003-08-07 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
WO2003082299A1 (en) * | 2002-04-03 | 2003-10-09 | Jencap Research Ltd. | Improved hormone replacement therapy |
EP1494679A4 (en) * | 2002-04-03 | 2009-10-28 | Barr Lab Inc | Step-down estrogen therapy |
EP1494679A1 (en) * | 2002-04-03 | 2005-01-12 | Barr Laboratories, Inc. | Step-down estrogen therapy |
US8841342B2 (en) | 2002-08-09 | 2014-09-23 | Vital Health Sciences Pty. Ltd. | Carrier |
WO2004022065A1 (en) * | 2002-09-05 | 2004-03-18 | Pantarhei Bioscience B.V. | Pharmaceutical application of 15- or 16- substituted testosterone analogues |
US7943602B2 (en) | 2002-09-05 | 2011-05-17 | Pantarhei Bioscience B.V. | Pharmaceutical application of 15- or 16-substituted testosterone analogues |
EP1583536A4 (en) * | 2003-01-17 | 2009-07-15 | Erik P Castle | Method of treatment of prostate cancer and composition for treatment thereof |
EP1583536A2 (en) * | 2003-01-17 | 2005-10-12 | Erik P. Castle | Method of treatment of prostate cancer and composition for treatment thereof |
EP1522306A1 (en) * | 2003-10-08 | 2005-04-13 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof |
WO2005037288A1 (en) * | 2003-10-08 | 2005-04-28 | Liconsa, Liberación Controlada de Sustancias Activas, S.A. | A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof |
US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
WO2007144151A1 (en) * | 2006-06-13 | 2007-12-21 | Bayer Schering Pharma Aktiengesellschaft | Step-down estrogen regimen for women receiving estrogen therapy |
US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
US9314527B2 (en) | 2010-03-30 | 2016-04-19 | Phosphagenics Limited | Transdermal delivery patch |
US9427400B2 (en) | 2010-10-19 | 2016-08-30 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
US11793669B2 (en) | 2013-11-14 | 2023-10-24 | The Population Council, Inc. | Combination therapy intravaginal rings |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
US11259956B2 (en) | 2013-11-14 | 2022-03-01 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
US10874638B2 (en) | 2014-01-17 | 2020-12-29 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
EP3613418A1 (en) * | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
WO2016028903A1 (en) * | 2014-08-20 | 2016-02-25 | Professional Compounding Centers Of America | Oral transmucosal pharmaceutical compositions including testosterone and a c-sperm |
US9452174B2 (en) | 2014-08-20 | 2016-09-27 | Professional Compounding Centers Of America | Oral transmucosal pharmaceutical compositions including testosterone and a C-SERM |
US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
WO2020010205A1 (en) * | 2018-07-05 | 2020-01-09 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
WO2020247653A1 (en) * | 2019-06-06 | 2020-12-10 | Evestra, Inc. | Hormonal contraception using a vaginal ring which releases estriol and trimegestone |
Also Published As
Publication number | Publication date |
---|---|
EP1187618A1 (en) | 2002-03-20 |
AU5181200A (en) | 2000-12-28 |
JP2003501390A (en) | 2003-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000074684A1 (en) | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use | |
Kupperman et al. | Contemporary therapy of the menopausal syndrome | |
Kuhl | Pharmacology of estrogens and progestogens: influence of different routes of administration | |
US5585370A (en) | Hormone preparation and method | |
JP5184727B2 (en) | Parenteral androgenic steroid administration to women | |
EP0559240B1 (en) | Contraceptive packages containing oestrogen and progestin | |
US7320970B2 (en) | Low dose estrogen interrupted hormone replacement therapy | |
US8338400B2 (en) | Methods and apparatus for transdermal or transmucosal application of testosterone | |
US4310523A (en) | Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate | |
RU2340345C2 (en) | Scheme of estrogen replenishment | |
US20030022877A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
DE602004002591T2 (en) | USE OF COMPOSITIONS CONTAINING AN ESTROGEN FOR THE TREATMENT AND PREVENTION OF MUSCLE SKIN NERVE | |
US5256421A (en) | Hormone preparation and method | |
HU221169B1 (en) | Use of estrogen and antiprogestin for producing pharmaceutical compositions useful in hormon replacement therapy and kit containing the same | |
JP2005514345A (en) | Composition for the treatment of female reproductive dysfunction after menopause | |
US9034854B2 (en) | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy | |
US20060014728A1 (en) | Hormone replacement therapy | |
JP2003511399A (en) | Mesoprogestin (progesterone receptor modulator) as a component of female contraceptives | |
EP0850647B1 (en) | Application of 11-substituted steroids for the preparation of medicaments with dissociated estrogenic activity | |
US20210386757A1 (en) | Methods of Treating Menopausal Symptoms Using Low Dose Progesterone | |
IE84449B1 (en) | Contraceptive packages containing oestrogen and progestin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 501220 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000936507 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000936507 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000936507 Country of ref document: EP |